Forbion — 2018 Investments

4 investments dated 2018 · listed companies and verified rows first · show all

Omeicos Therapeuticsomeicos.com in 𝕏Series C · Nov 2018 · $19M✓ verified

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases.

BiotechHealthtechBerlin, DE

Robert Fischer(CEO/CSO & Co-Founder)in Karen Uhlmann(Vice President Operations & IP, Co-Founder)inWolf-Hagen Schunck(Co-Founder)John R. Falck(Co-Founder)

Co-investorsRemiges Ventures, Inc.Vesalius Biocapital Partners

Enterprise Therapeuticsenterprisetherapeutics.com in 𝕏Series B · Apr 2018 · $41M

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.

BiotechHealthtechBrighton, GB

John Ford(Co-founder)in Martin Gosling(Founder)in

Co-investorsEpidarex Capital Novartis Venture Fund Versant Ventures IP Group Panakes Partners

Inflazomeinflazome.comSeries B · Nov 2018 · $46M

Co-investorsFountain Healthcare Partners Longitude Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Gotham Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.